BlackRock’s Turnstone Biologics TSBX Stock Holding History

BlackRock’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,066	Closed	-$383	–	5603
2025 Q2	$383	Sell	1,066 -41,334	-97%	-$14.5K	﹤0.01%	5383
2025 Q1	$17.4K	Sell	42,400 -792	-2%	-$337	﹤0.01%	5110
2024 Q4	$21.5K	Buy	43,192 +264	+0.6%	+$130	﹤0.01%	5092
2024 Q3	$23.9K	Buy	42,928 +1,584	+4%	+$2.43K	﹤0.01%	4917
2024 Q2	$108K	Sell	41,344 -622,060	-94%	-$1.78M	﹤0.01%	4683
2024 Q1	$1.74M	Buy	663,404 +361,479	+120%	+$1.03M	﹤0.01%	4047
2023 Q4	$768K	Buy	301,925 +20,519	+7%	+$53.6K	﹤0.01%	4322
2023 Q3	$1.11M	Buy	+281,406	New	+$2.51M	﹤0.01%	4211

BlackRock's TSBX Position: Q3 2025 in Review

BlackRock sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 1,066 shares — an estimated $383 sold.

BlackRock first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $1.74M in Q1 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

BlackRock reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
BlackRock sold 1,066 Turnstone Biologics shares in Q3 2025, an estimated $383.
BlackRock first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
BlackRock's Turnstone Biologics position peaked at $1.74M in Q1 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.